Livagen
Also known as: Lys-Glu-Asp-Ala, KEDA
Key Facts: Livagen
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Duration
- 10-30 day cycles
Mechanism of Action
The bioregulator hypothesis is that these very short peptides can enter cells and even the nucleus, where they interact with DNA or chromatin and influence which genes are read. For Livagen specifically, in-vitro work reported decondensation of pericentromeric heterochromatin (the densely coiled, mostly silent regions of chromosomes) and reactivation of ribosomal genes in cells from elderly donors. The idea is that aging packs chromatin tighter and shuts genes down, and that KEDA helps unpack it to restore gene activity. This remains a proposed mechanism rather than an established one, and how a four amino acid peptide would achieve such targeted epigenetic effects is not well explained by mainstream molecular biology.
Research Summary
The cited evidence for Livagen is narrow and comes overwhelmingly from Khavinson, Lezhava, and collaborators. The key study, published in the Bulletin of Experimental Biology and Medicine in 2002, exposed cultured lymphocytes from old people to Livagen and reported activation of ribosomal genes and decondensation of structural heterochromatin. Similar chromatin-reactivation effects were described across a set of related peptides (Vilon, Epitalon, Prostamax, Cortagen) in the same line of work. These are small, mechanistic, cell-level observations, not clinical outcomes. There are no registered randomized human trials of Livagen, no evidence it improves liver disease or any condition in people, and independent replication outside the originating institutions is essentially absent. Most online product descriptions extrapolate far beyond what the actual data shows. Treat Livagen as an experimental research compound with low-quality evidence.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Khavinson bioregulator for liver. Oral or sublingual. Run in 10-30 day cycles.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Sublingual or oral administration
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Limited safety data outside Russia
- ●Not FDA approved
References
- https://link.springer.com/article/10.1023/a:1021924702103
- https://pubmed.ncbi.nlm.nih.gov/37042594/
- https://www.mdpi.com/1420-3049/26/22/7053
- https://khavinson.info/assets/files/2004-Lezhava.pdf
Research This Peptide Further
Frequently Asked Questions
What does Livagen do?
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.
How does Livagen work?
The bioregulator hypothesis is that these very short peptides can enter cells and even the nucleus, where they interact with DNA or chromatin and influence which genes are read. For Livagen specifically, in-vitro work reported decondensation of pericentromeric heterochromatin (the densely coiled, mostly silent regions of chromosomes) and reactivation of ribosomal genes in cells from elderly donors. The idea is that aging packs chromatin tighter and shuts genes down, and that KEDA helps unpack it to restore gene activity. This remains a proposed mechanism rather than an established one, and how a four amino acid peptide would achieve such targeted epigenetic effects is not well explained by mainstream molecular biology.
Is Livagen FDA approved?
No, Livagen is not currently FDA approved. Current status: Preclinical research, approved in Russia as supplement
What are the side effects of Livagen?
Reported side effects include: Generally well-tolerated, Limited safety data outside Russia, Not FDA approved. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Livagen?
Community-reported common dose: 10-20 mg daily (Once or twice daily). Range: 10-20 mg daily. Administration: Oral capsules or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Livagen or used in similar applications.
Epithalon
Clinical TrialsEpithalon (also spelled Epitalon) is a synthetic four-amino-acid peptide, Ala-Glu-Asp-Gly (AEDG), modeled on a natural pineal gland extract. It came out of decades of Russian gerontology research led by Vladimir Khavinson and is marketed as an anti-aging compound that supposedly switches telomerase back on. It has no approval from the FDA, EMA, or other Western regulators, and the human evidence is thin.
BioregulatorsOvagen
PreclinicalOvagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.
BioregulatorsCortagen
PreclinicalCortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.
BioregulatorsVesugen
PreclinicalVesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson family of short peptide bioregulators, studied for vascular and neuroprotective effects. It is a research compound, not an approved drug, with no registered human clinical trials.
BioregulatorsChonluten
PreclinicalChonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.
BioregulatorsCrystagen
PreclinicalCrystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).
BioregulatorsWant updates on Livagen research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.